Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Innovent BiologicsSTU:6IB -6.27%80 Net Current Asset Value is €0.28 as of Dec. 2025, which is 100% below its 10-year median of 11.07. GuruFocus rates STU:6IB with a GF Score™ of 80/100 and a GF Value™ of €11.19 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 940 Biotechnology companies, Innovent Biologics ranks worse than 92.98% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Innovent Biologics's net current asset value per share for the quarter that ended in Dec. 2025 was €0.28.
The historical rank and industry rank for Innovent Biologics's Net Current Asset Value or its related term are showing as below:
STU:6IB'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 8.83 Med: 11.07 Max: 34.75
Current: 34.61
During the past 10 years, the highest Price-to-Net-Current-Asset-Value Ratio of Innovent Biologics was 34.75. The lowest was 8.83. And the median was 11.07.
STU:6IB's Price-to-Net-Current-Asset-Value is ranked worse than 92.98% of 940
companies
in the Biotechnology industry
Industry Median: 4.84
vs STU:6IB: 34.61
Innovent Biologics (STU:6IB) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Innovent Biologics Net Current Asset Value Related Terms
Innovent Biologics Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Innovent Biologics's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:6IB vs VRTX, REGN, ALNY: Net Current Asset Value Comparison
For the Biotechnology subindustry, Innovent Biologics's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innovent Biologics Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innovent Biologics's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Innovent Biologics's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of €0.28 mean?
Innovent Biologics (STU:6IB) has a Net Current Asset Value of €0.28 as of Dec. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Innovent Biologics and its competitors. This is 97% below median its historical median of 11.07. Over the past decade, Innovent Biologics' Net Current Asset Value has ranged from 8.83 to 34.75. According to the industry distribution chart, Innovent Biologics ranks #874 out of 940 companies in the Biotechnology industry, placing it in the top 93%.
Is Innovent Biologics' Net Current Asset Value too high?
Innovent Biologics' current Net Current Asset Value of €0.28 is 97% below median its 10-year median of 11.07. Over the past 10 years, this metric has ranged from a low of 8.83 to a high of 34.75. Based on the distribution chart, Innovent Biologics ranks #874 out of 940 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Innovent Biologics has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Innovent Biologics' Net Current Asset Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Innovent Biologics ranks #874 out of 940 companies for Net Current Asset Value. This places Innovent Biologics in the lower half of its industry. The industry median Net Current Asset Value is 4.84. Historically, Innovent Biologics' own Net Current Asset Value has ranged from 8.83 to 34.75 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.84, based on 940 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Innovent Biologics and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innovent Biologics's current Net Current Asset Value is €0.28, which is 97% below median its own 10-year median of 11.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovent Biologics stock overvalued right now?
Based on GuruFocus' analysis, Innovent Biologics (STU:6IB) is currently considered Modestly Undervalued. The stock's GF Value™ is €11.19, compared to a current price of €9.69 — trading 13.4% below its estimated fair value. The current Net Current Asset Value is €0.28, which is 97% below median its 10-year median of 11.07. Innovent Biologics' overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Innovent Biologics (STU:6IB), the current Net Current Asset Value is €0.28 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innovent Biologics (STU:6IB) Overvalued in 2026?
Based on GuruFocus' analysis, Innovent Biologics stock appears to be undervalued.
The current stock price of €9.69 is trading 13.4% below its estimated GF Value™ of €11.19.
GuruFocus considers Innovent Biologics to be Modestly Undervalued.
Key valuation signals for STU:6IB:
Net Current Asset Value: €0.28 (97% below median its 10-year median of 11.07)
GF Value™: €11.19 vs. price of €9.69 (13.4% below fair value)
No single metric tells the full story. See the STU:6IB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong stock exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs in its research and development pipeline. Its core assets are Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists (NRDL) for the first-line treatment of five major cancers, and mazdutide, a GLP-1/glucagon dual agonist drug for weight loss, fat breakdown, and Type 2 diabetes. Mazdutide is the first domestic GLP-1 drug produced and competes with Eli Lilly and Novo Nordisk in China. Tyvyt's main competition includes drugs from Junshi, Jiangsu Hengrui, BeOne, Merck, and Bristol Myers.
80GF Score
Get the complete analysis for STU:6IB
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:6IB has been successfully added to your 
